Sustained HIV Viral Suppression with Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though...
Main Authors: | Nagami, E.H (Author), Sax, P.E (Author), Thakarar, K. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01) -
Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01) -
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
by: Eugenia Bruzzese, et al.
Published: (2018-03-01) -
Multiple choices for HIV therapy with integrase strand transfer inhibitors
by: Raffi Francois, et al.
Published: (2012-12-01) -
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
by: Hyun Young Woo, et al.
Published: (2020-07-01)